Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

04-03-2026(Wed) 03-03-2026(Tue) 02-03-2026(Mon) 27-02-2026(Fri) 26-02-2026(Thu)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
1 Apr, 2026 (Wednesday)

            
HBM HOLDINGS-B(2142)
Analysis¡G
Harbour BioMed is a global biopharmaceutical company focused on the research and development of innovative drugs for immune diseases, oncology, and other therapeutic areas. The Group rapidly expands its innovative drug pipeline through independent R&D, collaborative development, and diversified partnership models. It has two core pillars ¡X Harbour Therapeutics and Nona Biosciences. Harbour Therapeutics focuses on advancing a pipeline of products with transformative therapeutic potential on a global scale. Nona Biosciences, leveraging the Group¡¦s strong technology platforms and professional expertise, accelerates global biotherapy innovation through an open and innovative business model, ultimately benefiting patients worldwide.
In 2025, the Group fully entered its 3.0 strategic phase, driven synergistically by three major growth engines: transforming Nona Biosciences into an AI-powered ¡§new infrastructure¡¨ for global antibody drug discovery; establishing long-term, platform-based strategic partnerships with multinational pharmaceutical companies to accelerate global expansion; and maximizing the global value of mid-to-late-stage assets in areas such as autoimmunity and oncology through Harbour Therapeutics. In terms of performance, for the year ended December 31, 2025, the Group recorded revenue of US$157.9 million, representing a year-on-year increase of 314.6%. Profit reached US$92.2 million, growing 31.9 times year-on-year.Regarding global collaborations, in March 2025, the Group entered into a global strategic cooperation agreement with AstraZeneca to develop next-generation multispecific antibody therapies for immune diseases, oncology, and various other conditions. Under the terms of the agreement, AstraZeneca will receive option rights for two preclinical immunology projects and will nominate additional targets for Harbour BioMed to develop next-generation multispecific antibody therapies. AstraZeneca may exercise these options to advance the projects into clinical development. In return, the Group will receive upfront payments, near-term milestone payments, and option exercise fees for additional new projects totaling up to US$175 million, as well as development and commercial milestone payments of up to US$4.4 billion, plus tiered royalties based on future net sales of the products. AstraZeneca also has the option to include more projects under the collaboration within the next five years and may extend the agreement for another five years upon mutual agreement. In addition, AstraZeneca subscribed for newly issued shares representing 9.15% of the Group for US$105 million. To advance the collaboration projects under the agreement and further joint initiatives, the Group will establish an innovation center in Beijing, China, together with AstraZeneca.
In June 2025, the Group¡¦s wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with Visterra to advance the development of Visterra¡¦s next-generation biologics pipeline for treating immune-mediated and autoimmune diseases, utilizing Nona¡¦s proprietary HCAb Harbour Mice technology platform. In the same month, the Group also reached a global strategic cooperation with Otsuka to jointly advance the development of HBM7020 (a BCMA¡ÑCD3 bispecific T-cell engager) for the treatment of autoimmune diseases. In November 2025, Nona Biosciences entered into a non-exclusive licensing agreement with Pfizer to accelerate preclinical antibody discovery for a range of potential disease indications. Under the agreement, Pfizer will gain global access to Nona Biosciences¡¦ proprietary HCAb technology platform to generate fully human heavy-chain-only antibodies. In return, Nona Biosciences will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. In December 2025, the Group entered into a long-term global strategic cooperation and licensing agreement with Bristol Myers Squibb to develop next-generation multispecific antibodies. In return, if Bristol Myers Squibb elects to advance all potential projects, the Group will receive payments totaling US$90 million, plus up to US$35 million in development and commercial milestone payments, and tiered royalties.(I do not hold the above stock.)
Strategy¡G
Buy-in Price: $12.80, Target Price: $14.10, Cut Loss Price: $12.10


VISEN PHARMA-B(2561)
Analysis¡G
Visen Pharmaceuticals is a biopharmaceutical company focused on innovative treatments for endocrine disorders. Operating in the late-stage development and near-commercialization phase, the company is committed to providing best-in-class or first-in-class therapies for unmet medical needs, including growth hormone deficiency, hypoparathyroidism, and achondroplasia. Leveraging its proprietary TransCon™ technology platform, the company has built a core pipeline consisting of TransCon hGH (lonapegsomatropin), TransCon PTH, and TransCon CNP. In 2025, the company reported revenue of RMB 165,000 and other income of RMB 11.94 million. Research and development costs amounted to RMB 93.48 million, representing a year-on-year increase of 3.27%. On January 26, 2026, the National Medical Products Administration (NMPA) approved the Biologics License Application for lonapegsomatropin for injection, indicated for the treatment of growth retardation due to growth hormone deficiency in children and adolescents aged 3 years and above in China. The company plans to commence full commercialization of lonapegsomatropin in 2026. We believe the company possesses significant advantages in its technology platform, product pipeline, and market positioning, and we are optimistic about its long-term development prospects.
Strategy¡G
Buy-in Price: $25.80, Target Price: $29.68, Cut Loss Price: $24.00



Report Review of Mar 2026

Automobile & Air (Zhang Jing)

This month I released updated reports of JOYSON(600699.CH), GWM(2333.HK), CX(293.HK), and Desay SV (002920.CH). Among them, we prefer JOYSON and GWM.

In 2025 the JOYSON's net profit attributable to owners of the parent company of approximately RMB1.336 billion (RMB, the same below), up 39.1% yoy. The Company attributes the growth in results to the gradual effectiveness of various profitability improvement and business integration measures implemented across global business regions in 2025, as well as the continued recovery in profitability of overseas operations. Through optimising and integrating its global operations, particularly achieving notable results in reducing global raw material costs and improving operational efficiency, the Company has significantly enhanced its operating performance and profitability. The Company's overall gross margin increased from 11.1% in 2022 to 14.5% in 2023, further rising to 16.2% in 2024, and continued to increase to 18.3% as of 2025. From a regional perspective, overseas markets have focused on continuously reducing raw material costs by introducing Chinese suppliers and optimising procurement prices from existing suppliers. Meanwhile, the Company's global operational improvement team has continued to optimise and enhance OEE (Overall Equipment Effectiveness) at overseas factories, while adjusting and relocating production capacity from high-cost countries/regions to low-cost countries/regions, thereby steadily driving gross margin improvement. In particular, cost improvement measures in the European region were implemented earlier and achieved significant gross margin enhancement during the reporting period. Cost improvement measures in the Americas were implemented relatively later, and gross margin is expected to improve correspondingly in the future, with profitability continuing to strengthen.

According to Frost & Sullivan, it is estimated that by 2029, the global and domestic market sizes of the automotive passive safety industry will grow to RMB213.6 billion and RMB49.7 billion, respectively, representing CAGR of 5.4% and 7.8%, respectively, from 2025. It is further expected that by 2029, the global and China automotive electronics market sizes will reach RMB3,330.3 billion and RMB1,892.6 billion, respectively, representing CAGR of 5.8% and 9.4%, respectively, from 2025. In 2024 the Company's market share in automotive safety products ranked second globally, with global and China market shares of 22.9% and 26.1%, respectively. As the Company firmly drives development through technological innovation in automotive electronics, maintaining intensive R&D investment in intelligent cockpit, intelligent driving, intelligent connectivity, vehicle-road-cloud coordination and high-voltage fast charging for new energy vehicles, it ensures sustained leadership in key technology areas and possesses long-term growth potential.

The Company has established strategic partnerships with several leading domestic and international robotics companies and has successfully launched a series of products, including AI-empowered robot head assemblies, integrated robot domain controllers and next-generation robot energy management solutions.

As a leading enterprise in automotive safety and automotive intelligence, JOYSON possesses strong R&D capabilities. Its automotive-related businesses are expected to continue benefiting from the global trends of vehicle electrification and intelligence, while its expansion into the humanoid robotics field is poised to open up a second growth curve.

We expect Joyson's EPS for 2025-2027 to be 0.88/1.19/1.43 yuan. We revised the target price of RMB 33.4 equivalent to 37.8/28.0/23.4x E P/E 2025-2027 and assign Buy ratings.

Sales volume of Great Wall Motor reached a record high of 1,324 thousand units in 2025, up 7.3% yoy, driven by the dual engines of new energy vehicles and overseas markets. Among them, EV sales reached 404 thousand units, up 25.4% yoy (the share of EVs increased by 4.4 ppts to 30.5%); overseas sales volume reached 506 thousand units, up 11.7% yoy (the share of overseas sales increased by 1.5 ppts to 38.2%).

Among the Company's sub-brands, Haval, WEY, Tank, Ora, and pickup recorded sales volume of 759 thousand, 102 thousand, 233 thousand, 48 thousand, and 182 thousand units, respectively, up 7.41%, up 86.29%, up 0.74%, down 23.68%, and up 2.57% yoy. The premium Tank brand maintained stable performance, while WEY delivered significant growth, with the WEY Gaoshan recording monthly deliveries exceeding 10 thousand units for three consecutive months. Against the backdrop of continuous optimisation in the vehicle sales structure, the ASP of a single vehicle increased steadily. In 2025, the Company's ASP rose up 2.7% yoy, or RMB4,400, to RMB168.3 thousand, reflecting further strengthening of the brand.

In January 2026, Great Wall Motor launched the world's first native AI full-powertrain platform ¡X GWM One. The platform is compatible with five powertrain types: PHEV, HEV, EV, FCEV, and ICE, covering seven vehicle categories including sedan, SUV, pickup, MPV, and sports cars. It is equipped with a self-developed 6C battery cell and a 900V architecture, alongside advanced intelligent cockpit and driver-assistance technologies. The Company plans to launch more than 50 new models in the future, covering all major vehicle segments and achieving "one architecture with full-scenario adaptability". The first flagship six-seat model based on the GWM One platform, the WEY V9X, is set to debut soon. With leading specification in power, range, handling and interior design, the model is expected to further solidify the Company's brand positioning in the premium segment.

The Company has set a sales volume target of 1.8 million units for 2026, including 600 thousand units from overseas markets, equivalent to an increase of 18.6%. We expect incremental growth to mainly come from the continued rollout of overseas localised production capacity and the accelerated expansion of overseas distribution channels (currently around 1,500 outlets). The Company has established three fully integrated vehicle manufacturing plants in Thailand, Brazil, and Russia, while also operating several KD plants in Pakistan, Vietnam, and Tunisia.

The Company has set resolute strategic objectives and clear steps for new energy and high-end-oriented transformation. The roll-out of a series of new models under a strong product cycle, deeper overseas market penetration, and improving channel networks, are expected to gradually generate scale effects, supporting the Company's continued growth momentum.

Considering latest financial forecast, we revised our target price to HK$17, equivalent to 13.2/9.5/7.6x P/E and 1.5/1.3/1.1x P/B in 2025/2026/2027. We gave the rating of "Buy".

Utilities, Commodity, Consumer Discretionary (Margaret Li)

This month I released 2 reports of MINISO (9896.HK) & CHICMAX (2145.HK).

MINISO is a global self-owned brand integrated retailer featuring IP design, mainly engaged in lifestyle home products and trendy toy cultural creations. Its core businesses include MINISO (value-for-money lifestyle products) and TOP TOY (trendy toys). Adopting an "IP collaboration + high cost-performance" model, the Company sells through a global store network covering toys, beauty, and lifestyle products. Since opening its first store in 2013, the Company has built a retail network spanning 112 countries and regions worldwide, with more than 7,700 stores globally and over 100 million cumulative registered members. Leveraging the dual-brand matrix of MINISO and TOP TOY, the Company has achieved multi-format synergies and built significant global channel advantages and user-base barriers.

The TOP TOY spin-off is approaching. In the first three quarters of 2025, TOP TOY store count reached 307, up 31% year-on-year, and revenue reached RMB1.317 billion, up 88% year-on-year. After completing Temasek strategic financing last year, its valuation has been anchored at RMB10 billion. We believe that if TOP TOY is successfully spun off while remaining a non-wholly-owned subsidiary of MINISO, it may bring multi-dimensional re-rating to the parent company through valuation premium, strategic focus, and capital-market catalysts, marking the formal value realization stage of MINISO's "second growth curve."

In January-February 2026, total retail sales of consumer goods reached RMB8,607.9 billion, up 2.8% year-on-year, 1.9 percentage points faster than in December last year. On a month-on-month basis, February total retail sales of consumer goods rose 0.81%. We believe MINISO is poised to become a global leading IP-driven retail platform. As its IP matrix continues to improve and globalization deepens, brand value and market share are expected to rise further. We forecast revenue of RMB21.445 billion, RMB26.163 billion, and RMB30.872 billion in 2025-2027, with EPS of RMB1.06/2.3/2.8 and corresponding P/E of 26.7x/12.4x/10.1x. We assign a target price of HK$39.2, corresponding to 15x 2026E P/E, and maintain a Buy rating.

Fig 1. Performance of Recommended Stocks

""
A stock is calculated by RMB yuan.
Source: Phillip Securities Research

Download PDF version...




Writer Info
Research Team
Tel: (852)22776555
Email:
research@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]